Doha, June 24 (QNA) - Hamad Medical Corporation (HMC), represented by the Nuclear Medicine Molecular Imaging section of the Clinical Imaging Department, has been accredited by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), USA, as a Radiopharmaceutical Therapy Centre of Excellence.

This recognition represents a significant milestone for HMC, placing it among the first centers outside the United States to receive this prestigious accreditation. It underscores the organization’s commitment to delivering advanced, high-quality radiopharmaceutical therapy services in line with international standards.

This accreditation reflects HMC’s dedication to providing therapy procedures to patients with the highest levels of quality, safety, and excellence. The team’s focus on precision, personalized, and targeted treatments continues to improve outcomes and enhance the patient experience.

Chief Radiologist at HMC Dr. Maryam Al Kuwari said: "Being recognized among the first centers outside the United States to achieve this distinction shows the strength of our capabilities and our focus on patient safety and personalized treatment. We are proud of this achievement and remain committed to advancing nuclear medicine services for our patients."

Currently, the Nuclear Medicine Molecular Imaging section in HMC provides treatment for six benign and malignant conditions, demonstrating its growing capability and leadership in this specialized field. The department continues to expand its services and innovate to meet the evolving needs of patients in Qatar and beyond. (QNA)